search
Back to results

An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation

Primary Purpose

Functional Constipation

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Proprietary Probiotic Blend
Placebo
Sponsored by
KGK Science Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Functional Constipation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male or female adults, aged 18 to 65 years
  • BMI of 18.5 kg/m2 to 35.0 kg/m2 (inclusive)
  • Subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
  • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • Double-barrier method (condoms with spermicide or diaphragm with spermicide)
  • Non-hormonal intrauterine devices
  • Vasectomy of partner
  • Non-heterosexual lifestyle
  • Subjects must have at least two of the following criteria based on subject self-reporting, for the past 3 months with the symptoms beginning at least 6 months ago:
  • Two or more criteria must be met by subjects:

    1. Straining during at least 25% of defecations
    2. Lumpy or hard stools in at least 25% of defecations
    3. Sensation of incomplete evacuation for at least 25% of defecations
    4. Sensation of anorectal obstruction/blockage for at least 25% of defecations
  • Fewer than three defecations per week
  • Loose stools are rarely present without the use of laxatives
  • Insufficient criteria for Irritable Bowel Syndrome
  • Subjects with an average stool type of < 3 on the Bristol Stool Scale as assessed over the two week run-in period (confirmed at baseline review of bowel habits diary).
  • Subjects who agree to maintain their current level of physical activity throughout the trial period.
  • Subjects who agree to discontinue the use of probiotic supplements including foods supplemented with probiotics (i.e. yogurts) or fiber supplements including foods labeled as supplemented with fiber
  • Subjects who agree to discontinue use of over-the-counter laxative medications (other than the rescue medication provided) within 2 weeks of screening and throughout the trial.
  • Subjects who successfully complete the run-in period by completing at least 80% of Run-In diary entries, 100% of IPAQ questionnaires and provide fecal sample.
  • Subjects who understand the nature and purpose of the study including the potential risks and side effects
  • Subjects who are willing to complete all study procedures including study related questionnaires and comply with study requirements
  • Subjects who have given voluntary, written, informed consent to participate in the study.

Exclusion Criteria:

  • Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.
  • Subjects with any unstable medical conditions
  • Subjects with any major diseases of the cardiovascular, renal, hepatic, gastrointestinal, pulmonary or endocrine systems
  • Subjects with Type I or Type II diabetes
  • Subjects with a history of major gastrointestinal complications (i.e. Crohn's disease, ulcer, cancer, ulcerative colitis)
  • History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable
  • Subjects with neurological disorders or significant psychiatric illnesses (significance determined by the Qualified Investigator)
  • Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis)
  • Subjects with any medical condition or a history of abdominal surgery that is deemed exclusionary by the Qualified Investigator
  • Subjects who have features which may suggest a more serious underlying cause of chronic constipation such as rectal bleeding, anemia, abrupt weight loss ( 5kg or more within the past month prior to randomization), gastrointestinal polyps, first degree family history of colorectal cancer.
  • Subjects with an active eating disorder
  • Subjects who have used an over-the-counter or prescription laxative medication within 2 weeks prior to screening.
  • Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched foods) within 4 weeks prior to screening
  • Subjects who have used an antibiotic within 4 weeks prior to screening
  • Subjects who have used medications in the investigators opinion known to cause constipation (i.e. opiates) within 4 weeks of screening
  • Subjects using Medicinal Marijuana
  • Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months
  • Subjects who currently consume greater than 2 standard alcoholic drinks per day.
  • Subjects who have participated in a clinical research trial within 30 days prior to randomization.
  • Subjects with an allergy or sensitivity to the investigational product ingredient
  • Subjects who are cognitively impaired and/or who are unable to give informed consent
  • Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Principle Investigator, may adversely affect the subjects' ability to complete the study or its measures or which may pose significant risk to the subject.

Sites / Locations

  • KGK Synergize Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Proprietary Probiotic Blend

Placebo

Arm Description

A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg

The placebo is administered to randomized healthy participants

Outcomes

Primary Outcome Measures

Changes in the symptoms of constipation as measured by the PAC SYM questionnaire

Secondary Outcome Measures

Changes in stool consistency as measured by the Bristol Stool Scale
Changes in stool frequency
Weekly mean Complete Spontaneous Bowel Movements
Changes in quality of life questionnaire score
Changes in microbial composition of feces

Full Information

First Posted
March 6, 2015
Last Updated
December 12, 2017
Sponsor
KGK Science Inc.
Collaborators
UAS Labs LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT02418507
Brief Title
An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
May 29, 2015 (Actual)
Primary Completion Date
April 1, 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
KGK Science Inc.
Collaborators
UAS Labs LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective for this study is to monitor the change in patient assessed symptoms of constipation in subjects taking the proprietary probiotic blend compared to those taking the placebo. The secondary objective for this study is to additionally monitor changes in stool consistency, stool frequency, quality of life and microbial composition of feces from baseline to Day 29, in all subjects. Safety considerations monitored any changes in blood safety parameters as well as incidence of adverse events throughout the entire study for all subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Constipation

7. Study Design

Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Proprietary Probiotic Blend
Arm Type
Active Comparator
Arm Description
A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The placebo is administered to randomized healthy participants
Intervention Type
Dietary Supplement
Intervention Name(s)
Proprietary Probiotic Blend
Intervention Description
A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
The placebo is administered to randomized healthy participants
Primary Outcome Measure Information:
Title
Changes in the symptoms of constipation as measured by the PAC SYM questionnaire
Time Frame
Baseline to Day 29
Secondary Outcome Measure Information:
Title
Changes in stool consistency as measured by the Bristol Stool Scale
Time Frame
Baseline to Day 29
Title
Changes in stool frequency
Description
Weekly mean Complete Spontaneous Bowel Movements
Time Frame
Baseline to Day 29
Title
Changes in quality of life questionnaire score
Time Frame
Baseline to Day 29
Title
Changes in microbial composition of feces
Time Frame
Baseline to Day 29
Other Pre-specified Outcome Measures:
Title
Changes in blood safety parameters
Description
CBC, electrolytes, creatinine, AST, ALT, GGT and bilirubin
Time Frame
Baseline to Day 29

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male or female adults, aged 18 to 65 years BMI of 18.5 kg/m2 to 35.0 kg/m2 (inclusive) Subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method (condoms with spermicide or diaphragm with spermicide) Non-hormonal intrauterine devices Vasectomy of partner Non-heterosexual lifestyle Subjects must have at least two of the following criteria based on subject self-reporting, for the past 3 months with the symptoms beginning at least 6 months ago: Two or more criteria must be met by subjects: Straining during at least 25% of defecations Lumpy or hard stools in at least 25% of defecations Sensation of incomplete evacuation for at least 25% of defecations Sensation of anorectal obstruction/blockage for at least 25% of defecations Fewer than three defecations per week Loose stools are rarely present without the use of laxatives Insufficient criteria for Irritable Bowel Syndrome Subjects with an average stool type of < 3 on the Bristol Stool Scale as assessed over the two week run-in period (confirmed at baseline review of bowel habits diary). Subjects who agree to maintain their current level of physical activity throughout the trial period. Subjects who agree to discontinue the use of probiotic supplements including foods supplemented with probiotics (i.e. yogurts) or fiber supplements including foods labeled as supplemented with fiber Subjects who agree to discontinue use of over-the-counter laxative medications (other than the rescue medication provided) within 2 weeks of screening and throughout the trial. Subjects who successfully complete the run-in period by completing at least 80% of Run-In diary entries, 100% of IPAQ questionnaires and provide fecal sample. Subjects who understand the nature and purpose of the study including the potential risks and side effects Subjects who are willing to complete all study procedures including study related questionnaires and comply with study requirements Subjects who have given voluntary, written, informed consent to participate in the study. Exclusion Criteria: Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study. Subjects with any unstable medical conditions Subjects with any major diseases of the cardiovascular, renal, hepatic, gastrointestinal, pulmonary or endocrine systems Subjects with Type I or Type II diabetes Subjects with a history of major gastrointestinal complications (i.e. Crohn's disease, ulcer, cancer, ulcerative colitis) History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable Subjects with neurological disorders or significant psychiatric illnesses (significance determined by the Qualified Investigator) Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis) Subjects with any medical condition or a history of abdominal surgery that is deemed exclusionary by the Qualified Investigator Subjects who have features which may suggest a more serious underlying cause of chronic constipation such as rectal bleeding, anemia, abrupt weight loss ( 5kg or more within the past month prior to randomization), gastrointestinal polyps, first degree family history of colorectal cancer. Subjects with an active eating disorder Subjects who have used an over-the-counter or prescription laxative medication within 2 weeks prior to screening. Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched foods) within 4 weeks prior to screening Subjects who have used an antibiotic within 4 weeks prior to screening Subjects who have used medications in the investigators opinion known to cause constipation (i.e. opiates) within 4 weeks of screening Subjects using Medicinal Marijuana Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months Subjects who currently consume greater than 2 standard alcoholic drinks per day. Subjects who have participated in a clinical research trial within 30 days prior to randomization. Subjects with an allergy or sensitivity to the investigational product ingredient Subjects who are cognitively impaired and/or who are unable to give informed consent Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Principle Investigator, may adversely affect the subjects' ability to complete the study or its measures or which may pose significant risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tetyana Pelipyagina, MD
Organizational Affiliation
tetyana@kgksynergize.com
Official's Role
Principal Investigator
Facility Information:
Facility Name
KGK Synergize Inc.
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5R8
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation

We'll reach out to this number within 24 hrs